Monopar Therapeutics
MNPR | NASDAQ
$71.97
-$0.03 (-0.04%)
At close: Nov 16, 2026, 4:00 PM ET
$71.97
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-0.04%
(1D)No price chart data available for 1D timeframe.
Rating
23.5
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #959/1021 (Top 94%)
Key Statistics
Market Data
Market Cap $616.16M
1D Range
70.34 75.09
52W Range
50.12 123.84
Valuation (TTM)
PE -27.90
PB 4.85
EV/EBITDA -23.64
Valuation (NTM)
Forward PE N/A
Forward PEG -0.48
Price Target $125.00
Cash Flow
FCF Yield -529.2%
SBC Adj. FCF Yield -761.8%
SBC Impact -44.0%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y -60.3% |
-37.0%
FCF 3Y | 5Y -149.0% |
-98.8%
Returns
ROA -15.8%
ROE -15.5%
ROIC -20.0%
Financial Health
Net Cash
$129.45M
Current Ratio 43.55
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage,...
Sector Healthcare
Industry Biotechnology
Employees 22
IPO Date Dec 19, 2019
Website www.monopartx.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
5
Consensus
Buy
Price Target
$125.00
Upside
+73.68%
Buy (4)
Hold (1)
Sell (0)
Add to Watchlist
Select watchlists to add or remove MNPR